Probatebeta
Target

DRD2

Dopamine receptor D2

As of the edition of 20 October 2026, DRD2 (dopamine receptor D2, UniProt P14416) has 93 drugs tested at it and 75 companies on the list, 7 on route A and 22 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P14416
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
12
Disease areas
Mental health; Nervous system; Cancer; Nutrition and metabolism; Chemically induced; Digestive system; Urinary and reproductive; Hormones
Registered trials of its drugs
2,254

Drugs at this target

StatusCount
Marketed67
Active4
Went quiet4
Stopped10
Withdrawn from market7
Status not established1
Total93
DrugStatusFurthest phaseUS protection
RisperidoneMarketedPhase 4none listed
OlanzapineMarketedPhase 4none listed
QuetiapineMarketedPhase 4none listed
AripiprazoleMarketedPhase 4none listed
PramipexoleMarketedPhase 4none listed
PaliperidoneMarketedPhase 4none listed
ZiprasidoneMarketedPhase 4none listed
MetoclopramideMarketedPhase 4none listed
BrexpiprazoleMarketedPhase 4Ends 2028
RotigotineMarketedPhase 4none listed
LurasidoneMarketedPhase 4none listed
HaloperidolMarketedPhase 4none listed

12 of 93 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A7
Route B22
Engaged14
Undetermined32
Total on the list75
Three companies on route A or B, with the route only
CompanyRoute
NovartisRoute B
Merck & Co.Route B
AlkermesRoute B

The other 72 companies at DRD2

In the product

75 companies in all; 72 are not named here, and no score is.

See the 75 companies at DRD2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at DRD2

Other targets in mental health

Companies holding approvals at DRD2